BioMarin stock gains Morgan Stanley coverage with overweight rating

Morgan Stanley resumed coverage on BioMarin Pharmaceutical with an Overweight rating and a $120 price target, implying more than 2x upside from the current $53.18 share price. The call cites undervaluation, a 7.3% WACC DCF, and improving free cash flow and earnings, with EPS forecast to reach $5.20 in FY2026. Additional positives include French clearance for the Amicus merger, encouraging VOXZOGO data, and supportive ratings from Wolfe Research ($95) and Jefferies ($103).

Analysis

The setup in BMRN is less about the next print and more about whether the market is forced to re-rate it from a binary orphan-drug story into a multi-year cash compounder. The key second-order effect is that a stable slope in the core franchise can finance pipeline optionality and delever equity holders from single-asset risk; that tends to compress the equity risk premium faster than headline revenue growth alone. If that transition sticks, the next leg is multiple expansion before earnings revisions fully catch up.

The market is still likely underappreciating how much of the upside comes from duration, not just peak sales. In rare disease, even modest durability improvements can translate into outsized NPV changes because cash flows are long-dated and capex-light; that makes the DCF sensitivity highly convex to both terminal growth and discount rate assumptions. The flip side is that if VOXZOGO durability or new-label expansion stalls, the stock can de-rate sharply even if near-term numbers look fine.

M&A completion reduces one overhang but introduces integration risk and capital allocation scrutiny. A cleaner governance structure can support a higher multiple only if management proves it can convert strategic complexity into operating leverage rather than expense creep; otherwise, the market will treat the merger as financial engineering and fade the rerating. Near term, the catalyst path is data-and-guidance driven, but the true inflection is likely over the next 2-6 quarters as investors see whether free cash flow inflects in a straight line.

The contrarian view is that consensus may be extrapolating a smooth transition that biotech rarely delivers. The current setup may already embed a fair amount of optimism on pipeline diversification, so the risk/reward is best expressed with defined downside and time decay, not outright stock ownership alone. Any disappointment in post-deal integration, VOXZOGO trajectory, or additional trial attrition would hit the multiple before it hits the earnings model.

Key Decisions for Investors

• Buy BMRN on weakness into the next 2-4 weeks, with a 6-12 month horizon; use a starter position only, because the rerating thesis depends on execution through 2026 and not just sentiment.
• For defined risk, buy BMRN Jan-2026 or Jan-2027 call spreads to express the multiple-expansion view; upside is tied to a re-rate if free cash flow inflects, while premium paid caps downside if the market stays skeptical.
• Pair trade: long BMRN / short a basket of higher-beta single-asset rare disease names over the next 3-6 months; the relative value thesis is that BMRN should migrate to a compounder multiple while weaker platforms remain hostage to one program.
• If already long, sell out-of-the-money calls against the position into any post-catalyst pop; the stock’s upside is real but likely path-dependent, and covered-call harvest improves carry while waiting for operating leverage to show up.
• Set a hard risk stop if the market starts assigning a punitive read-through to VOXZOGO or if post-merger execution slips; in that case the thesis breaks because the valuation rerate is more fragile than the operating story.